Hirawat Samit (CIK 1781290) reported 15 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-06-12). Recent activity: Buy PCRX (6,405 shares), Buy BMY (4,250 shares), Buy BMY (4,886 shares), Sell BMY (337 shares), Sell BMY (2,327 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Pacira BioSciences, Inc. (PCRX) | Director | Buy | 6,405 | $0 |
| 2025-04-29 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,250 | $202,215 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,886 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 337 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 2,327 | $146,857 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 4,765 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 831 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 2,013 | $127,040 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 5,854 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 998 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 2,484 | $156,765 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 28,593 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 10,545 | $0 |
| 2025-03-12 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Sell | 9,232 | $582,632 |
| 2025-02-19 | BRISTOL MYERS SQUIBB CO (BMY) | EVP,Chief Med.Offr.,Drug Dev. | Buy | 1,823 | $100,000 |
Source: SEC Form 4 filings · as of 2026-06-12